Status:
WITHDRAWN
The LEAD COVID-19 Trial: Low-risk, Early Aspirin and Vitamin D to Reduce COVID-19 Hospitalizations
Lead Sponsor:
Louisiana State University Health Sciences Center in New Orleans
Conditions:
COVID
Vitamin D Deficiency
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
Although the novel SARS-CoV-2 virus (COVD-19) is classified as an acute respiratory infection, emerging data show that morbidity and mortality are driven by disseminated intravascular coagulopathy. Un...
Detailed Description
Although the novel SARS-CoV-2 virus (COVD-19) is classified as an acute respiratory infection, emerging data show that morbidity and mortality are driven by disseminated intravascular coagulopathy. Da...
Eligibility Criteria
Inclusion
- Patients \> 18 years
- Written informed consent
- New (within 24 hours) COVID-19 diagnosis
Exclusion
- Pregnant patients or Prisoners
- History of GI bleeding or peptic ulcer disease, or spontaneous bleeding from other sites; History of thrombocytopenia; History of chronic kidney disease; Concurrent use of nonsteroidal anti-inflammatory drugs, or steroids.
- Hypervitaminosis D and associated risk factors: Renal failure, Liver failure, Hyperparathyroidism, Sarcoidosis, Histoplasmosis
Key Trial Info
Start Date :
May 1 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2020
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT04363840
Start Date
May 1 2020
End Date
December 1 2020
Last Update
December 27 2021
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.